Skip to main content

Neurocrine Biosciences

Neurocrine Biosciences, Inc. is an American biopharmaceutical enterprise that discovers, develops, and commercializes pharmaceutical products for neurological and endocrine disorders. The company directs its research focus toward complex diseases affecting the central nervous system and endocrine pathways. Its principal products encompass FDA-approved therapeutics for the treatment of tardive dyskinesia, chorea associated with Huntington's disease, and congenital adrenal hyperplasia. Revenue is driven primarily through the commercial sale of proprietary pharmaceutical products within domestic healthcare markets. The primary end markets comprise neurological and psychiatric patients treated by specialized healthcare practitioners and hospitals. As an established biotechnology enterprise in neuroscience, the firm holds a notable position in specialty therapeutics. Headquartered in San Diego, California, Neurocrine Biosciences Inc. is publicly listed on NASDAQ under the ticker symbol NBIX.

47 of the funds FundTelligence covers report a position in Neurocrine Biosciences.

Legal name
Neurocrine Biosciences Inc.
Sector
Health Care
Country
United States
Funds holding it
47

Funds holding Neurocrine Biosciences

Showing the 8 largest of 47 funds holding it.

Loading...